Retatrutide, developed by Soma Corp., is receiving considerable attention as a innovative treatment for obesity regulation. This unique drug combines the activity of a GLP-1 receptor agonist and a GIP receptor agonist , aiming to simply promote reduced body fat but also improve related metabolic issues . Initial human trials have demonstrated promi